Literature DB >> 21535159

Pathophysiology of acquired von Willebrand disease: a concise review.

Shrimati Shetty1, Priyanka Kasatkar, Kanjaksha Ghosh.   

Abstract

Acquired von Willebrand disease (AVWD) is a rare, underdiagnosed hemorrhagic disorder, which is similar to congenital VWD with regard to the clinical and laboratory parameters; however, it is found in individuals with no positive family history and has no genetic basis. The etiology is varied, the commonest being hematoproliferative disorders and cardiovascular disorders. Other disorders associated with AVWD are autoimmune disorders such as systematic lupus erythematosus, hypothyroidism, and neoplasia, or it may also be drug induced. In quite a few cases, the etiology is unknown. The pathogenic mechanisms are different in different underlying disorders or they may be overlapping among these disorders. Some of the proposed mechanisms include the development of autoantibodies, selective absorption of high molecular weight von Willebrand factor (VWF) multimers, non-selective absorption of VWF, mechanical destruction of VWF under high shear stress, and increased proteolysis. This report presents a concise review of the pathophysiological mechanisms of AVWD in these various underlying conditions.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21535159     DOI: 10.1111/j.1600-0609.2011.01636.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  10 in total

Review 1.  [Current coagulation diagnostics in intensive care medicine].

Authors:  T Lang
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-11-06       Impact factor: 0.840

Review 2.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

Review 3.  Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.

Authors:  Sujoy Ray; Amita Ray
Journal:  Cochrane Database Syst Rev       Date:  2016-11-10

4.  Acquired von Willebrand's disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland.

Authors:  Geoffrey Spencer Chilvers; Graham Porter
Journal:  BMJ Case Rep       Date:  2014-08-05

5.  Successful management of severe refractory acquired immune bleeding disorder: Prior to insisting surgery.

Authors:  Hassan Al-Jafar; H Al-Barjas; Raed A Hashem; Thanaa M K Refaii; Ahmad M AlSaeed
Journal:  Int J Surg Case Rep       Date:  2014-10-31

6.  Acquired von Willebrand Disease Associated with Monoclonal Gammopathy of Unknown Significance.

Authors:  Sijan Basnet; Catherine Lin; Rashmi Dhital; Izza Mir; Elan Mohanty; Biswaraj Tharu; Sushil Ghimire; Dilli Ram Poudel
Journal:  Case Rep Oncol Med       Date:  2017-11-01

7.  Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature.

Authors:  Eva Jennes; Dorothee Guggenberger; Rainer Zotz; Lora Thompson; Tim H Brümmendorf; Steffen Koschmieder; Edgar Jost
Journal:  Clin Case Rep       Date:  2017-03-30

8.  Acquired von Willebrand Disease Secondary to Clear Cell Renal Cell Carcinoma.

Authors:  Brian Odom; Iyad Khourdaji; Victoria Golas; Richard Zekman; Bradley Rosenberg
Journal:  J Endourol Case Rep       Date:  2018-07-01

9.  Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13.

Authors:  Kis Djamiatun; Andre J A M van der Ven; Philip G de Groot; Sultana M H Faradz; D Hapsari; Wil M V Dolmans; Silvie Sebastian; Rob Fijnheer; Quirijn de Mast
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01

10.  Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.

Authors:  Paolo Rossato; Helmut Glantschnig; Peter Leidenmühler; Alexandra Kopic; Tanja Ruthsatz; Bernhard Majer; Maria Schuster; Friedrich Scheiflinger; Werner Höllriegl
Journal:  Blood Coagul Fibrinolysis       Date:  2022-01-01       Impact factor: 1.061

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.